SCHEMBL24257522

SCHEMBL24257522

Cc1c(-c2cccc(Oc3ccccc3)c2)cnc(C#N)c1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 1/20 0.40
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
MAOB P27338 5/20 0.38
NR1H2 P55055 3/20 0.38
NR1H3 Q13133 3/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NAAA Q02083 2/20 0.37
CYP11B1 P15538 2/20 0.37
MAPT P10636 2/20 0.37
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257562 0.91 MAOB (0.47) SQORMAOBNR1H2NR1H3MEN1
SCHEMBL30546831 0.91 MAOB (0.47) SQORMAOBNR1H2NR1H3MEN1
SCHEMBL24257768 0.88 SQOR (0.42) SQORGABRG2GABRB3GABRA5GABRA3
SCHEMBL30452737 0.86 GRM5 (0.42) SQORGABRG2GABRB3GABRA5GABRA3
SCHEMBL30546869 0.86 C5AR1 (0.41) SQORGABRG2GABRB3GABRA5GABRA3
SCHEMBL24257771 0.86 GRM5 (0.42) SQORGABRG2GABRB3GABRA5GABRA3
SCHEMBL24257769 0.86 C5AR1 (0.41) SQORGABRG2GABRB3GABRA5GABRA3
SCHEMBL30546879 0.84 HSD17B10 (0.43) SQORMAOBMEN1ALDH1A1KMT2A
SCHEMBL24257819 0.84 HSD17B10 (0.43) SQORMAOBMEN1ALDH1A1KMT2A
SCHEMBL24257578 0.81 CYP11B1 (0.47) SQORMEN1ALDH1A1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 SQOR 756/4885GABRG2 3174/4885GABRB3 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.